HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background

Oncogene

Volumn 27, Issue 12, 2008, Pages 1800-1804

  Massimi, P ^a   Shai, A ^b   Lambert, P ^b   Banks, L ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

E6AP; HPV E6; p53; PDZ; Proteasome

Indexed keywords

PDZ PROTEIN; PROTEASOME; PROTEIN E6; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

CELL LINE; DNA-BINDING PROTEINS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PDZ DOMAINS; REPRESSOR PROTEINS; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 40749122639     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210810     Document Type: Article

References (29)

1. Camus S, Menendez S, Cheok C, Stevenson L, Lain S, Lane D. (2007). Ubiquitin-independent degradation of p53me diated by high-risk human papillomavirus protein E6. Oncogene 26: 4059-4070.
2. Cooper B, Schneider S, Bohl J, Jiang Y, Beaudet A, Vande Pol S. (2003). Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306: 87-99.
3. Gardiol D, Banks L. (1998). Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53structure and cell type but little difference with respect to mutants of HPV-18 E6. J Gen Virol 79: 1963-1970.
4. Gardiol D, Kühne C, Glaunsinger B, Lee SS, Javier R, Banks L. (1999). Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18: 5487-5496.
5. Glaunsinger B, Lee S, Thomas M, Banks L, Javier R. (2000). Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19: 5270-5280.
6. Grm H, Banks L. (2004). Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J Gen Virol 85: 2815-2819.
7. Hengstermann A, D'Silva M, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M. (2005). Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 79: 9296-9300.
8. Huibregtse J, Scheffner M, Howley P. (1993). Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13: 775-784.
9. Jiang Y, Armstrong D, Albrecht U, Atkins C, Noebels J, Eichele G et al. (1998). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53and deficits of contextual learning and long-term potentiation. Neuron 21: 799-811.
10. Kelley M, Keiger K, Lee C, Huibregtse J. (2005). The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 79: 3737-3747.
11. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. (1997). Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94: 11612-11616.
12. Latorre IJ, Roh MH, Frese KK, Weiss RS, Margolis B, Javier RT. (2005). Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 118: 4283-4293.
13. Lee C, Laimins L. (2004). Role of the PDZ domain-containing motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 78: 12366-12377.
14. Lee S, Glaunsinger B, Mantovani F, Banks L, Javier R. (2000). Multi-PDZ domain protein MUPP1 is a cellular target for both Adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 74: 9680-9693.
15. Lee S, Weiss R, Javier R. (1997). Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 94: 6670-6675.
16. Liu Y, Chen J, Gao Q, Dalal S, Hong Y, Mansur C et al. (1999). Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73: 7297-7307.
17. Munger K, Basile J, Duensing S, Eichten A, Gonzalez S, Grace M et al. (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898.
18. Nakagawa S, Huibregtse J. (2000). Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20: 8244-8253.
19. Nguyen M, Nguyen M, Lee D, Griep A, Lambert P. (2003). The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 77: 6957-6964.
20. Pim D, Thomas M, Javier R, Gardiol D, Banks L. (2000). HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 19: 719-725.
21. Scheffner M, Huibregtse J, Viestra R, Howley P. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
22. Scheffner M, Werness B, Huibregtse J, Levine A, Howley P. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
23. Shai A, Brake T, Somoza C, Lambert PF. (2007). The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67: 1626-1635.
24. Storrs CH, Silverstein SJ. (2007). PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isofcrm 18 E6. J Virol 81: 4080-4090.
25. Thomas M, Kalita A, Labreque S, Pim D, Banks L, Matlashewski G. (1999a). Two polymorphic variants of wild-type p53differ biochemically and biologically. Mol Cell Biol 19: 1092-1100.
26. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L et al. (2002). Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3proteins for degradation. Oncogene 21: 5088-5096.
27. Thomas M, Massimi P, Navarro C, Borg J-P, Banks L. (2005). The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24: 6222-6230.
28. Thomas M, Pim D, Banks L. (1999b). The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18: 7690-7700.
29. zur Hausen H. (1996). Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78.